Can philanthropy fill the gap left by the closure of USAID? Unlikely, say the experts — but it can do something.

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).